The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Open accessAbstract
Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17, the major effector cytokine in the pathogenesis of psoriatic disease, along with the rationale for targeting the IL-17 cytokine family (IL-17A, IL-17F, and IL-17 receptor A) in the treatment of psoriasis and psoriatic arthritis. Emerging evidence indicates that major sources of IL-17A in patients with psoriatic disease are mast cells, γδ T cells, αβ T cells, and innate lymphoid cells in lesional skin and synovial fluid. Within the skin and joints, IL-17A acts on cellular targets, including keratinocytes, neutrophils, endothelial cells, fibroblasts, osteoclasts, chondrocytes, and osteoblasts, to stimulate production of various antimicrobial peptides, chemokines, and proinflammatory and proliferative cytokines, which, in turn, promote tissue inflammation and bone remodeling. The critical importance of the IL-23/IL-17A axis to the pathogenesis of psoriatic disease has resulted in many new biologic treatments targeting these cytokines. These biologics dramatically improve skin and joint symptoms in patients with moderate-to-severe psoriasis and psoriatic arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo
Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00243-6 · Cited by 1,203
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S. I., Hupé, P., Barillot, E., & Soumelis, V. (2008) · Nature Immunology · doi:10.1038/ni.1613 · Cited by 938
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Blauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y.-K., Li, S., & Kimball, A. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.041 · Cited by 897
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Self-citationGriffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
A protective function for interleukin 17A in T cell–mediated intestinal inflammation
O'Connor Jr, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K., & Flavell, R. A. (2009) · Nature Immunology · doi:10.1038/ni.1736 · Cited by 756
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Regulation of inflammatory responses by IL-17F
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071978 · Cited by 739
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Self-citationIL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner
Wei, L., Laurence, A., Elias, K. M., & O'Shea, J. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705100200 · Cited by 641
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.399 · Cited by 640
Self-citationMease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Self-citationHymowitz, S. G., Filvaroff, E. H., Yin, J., Lee, J., Cai, L., Risser, P., Maruoka, M., Mao, W., Foster, J., Kelley, R. F., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.19.5332 · Cited by 548
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G., Feldmeyer, L., Marinari, B., Chon, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6621 · Cited by 539
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tyring, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 514
Self-citationHarper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Self-citationBasic biology and role of interleukin‐17 in immunity and inflammation
Zenobia, C., & Hajishengallis, G. (2015) · Periodontology 2000 · doi:10.1111/prd.12083 · Cited by 470
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
Stritesky, G. L., Yeh, N., & Kaplan, M. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.5948 · Cited by 417
Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines
Fitch, E., Harper, E., Skorcheva, I., Kurtz, S. E., & Blauvelt, A. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0075-1 · Cited by 415
Self-citationTaylor, P. R., Roy, S., Leal, S. M., Sun, Y., Howell, S. J., Cobb, B. A., Li, X., & Pearlman, E. (2014) · Nature Immunology · doi:10.1038/ni.2797 · Cited by 410
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Villanova, F., Flutter, B., Tosi, I., Grys, K., Sreeneebus, H., Perera, G. K., Chapman, A., Smith, C. H., Di Meglio, P., & Nestle, F. O. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.477 · Cited by 386
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Melanocyte antigen triggers autoimmunity in human psoriasis
Arakawa, A., Siewert, K., Stöhr, J., Besgen, P., Kim, S.-M., Rühl, G., Nickel, J., Vollmer, S., Thomas, P., Krebs, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151093 · Cited by 361
Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
Li, H., Chen, J., Huang, A., Stinson, J., Heldens, S., Foster, J., Dowd, P., Gurney, A. L., & Wood, W. I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.773 · Cited by 354
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D., Iversen, L., & Kragballe, K. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08902.x · Cited by 352
Teunissen, M. B. M., Munneke, J. M., Bernink, J. H., Spuls, P. I., Res, P. C. M., te Velde, A., Cheuk, S., Brouwer, M. W. D., Menting, S. P., Eidsmo, L., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.146 · Cited by 335
Starnes, T., Broxmeyer, H. E., Robertson, M. J., & Hromas, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.642 · Cited by 331
Res, P. C. M., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., & Teunissen, M. B. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014108 · Cited by 328
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14433 · Cited by 313
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Self-citationKeratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Zaba, L. C., Suárez-Fariñas, M., Fuentes-Duculan, J., Nograles, K. E., Guttman-Yassky, E., Cardinale, I., Lowes, M. A., & Krueger, J. G. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.046 · Cited by 303
van de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Self-citationClinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch, I. R., Robins, H. S., Kupper, T. S., Krueger, J. G., & Clark, R. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93396 · Cited by 285
Recent advances in the IL-17 cytokine family
Gaffen, S. L. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.07.006 · Cited by 283
Hijnen, D., Knol, E. F., Gent, Y. Y., Giovannone, B., Beijn, S. J. P., Kupper, T. S., Bruijnzeel-Koomen, C. A. F. M., & Clark, R. A. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.456 · Cited by 271
Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E
Chang, S. H., Reynolds, J. M., Pappu, B. P., Chen, G., Martinez, G. J., & Dong, C. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.010 · Cited by 271
Interleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis
Noordenbos, T., Yeremenko, N., Gofita, I., van de Sande, M., Tak, P. P., Caňete, J. D., & Baeten, D. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33396 · Cited by 270
Glatt, S., Baeten, D., Baker, T., Griffiths, M., Ionescu, L., Lawson, A. D. G., Maroof, A., Oliver, R., Popa, S., Strimenopoulou, F., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212127 · Cited by 270
Ortega, C., Fernández-A, S., Carrillo, J. M., Romero, P., Molina, I. J., Moreno, J. C., & Santamaría, M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109046 · Cited by 269
Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reißig, S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304108 · Cited by 261
Th17 and Th22 cells in psoriatic arthritis and psoriasis
Benham, H., Norris, P., Goodall, J., Wechalekar, M. D., FitzGerald, O., Szentpetery, A., Smith, M., Thomas, R., & Gaston, H. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4317 · Cited by 253
Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease
Xu, X.-R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3255 · Cited by 245
Kirkham, B. W., Kavanaugh, A., & Reich, K. (2014) · Immunology · doi:10.1111/imm.12142 · Cited by 243
IL-23–Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A
Rizzo, H. L., Kagami, S., Phillips, K. G., Kurtz, S. E., Jacques, S. L., & Blauvelt, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001001 · Cited by 238
Self-citationCCR6 is required for IL-23–induced psoriasis-like inflammation in mice
Hedrick, M. N., Lonsdorf, A. S., Shirakawa, A.-K., Lee, C.-C. R., Liao, F., Singh, S. P., Zhang, H. H., Grinberg, A., Love, P. E., Hwang, S. T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37378 · Cited by 238
β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
Kolbinger, F., Loesche, C., Valentin, M.-A., Jiang, X., Cheng, Y., Jarvis, P., Peters, T., Calonder, C., Bruin, G., Polus, F., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.038 · Cited by 238
Boutet, M.-A., Nerviani, A., Gallo Afflitto, G., & Pitzalis, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020530 · Cited by 226
Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related Genes
Suárez-Fariñas, M., Fuentes-Duculan, J., Lowes, M. A., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.280 · Cited by 215
Reich, K., Papp, K. A., Matheson, R. T., Tu, J. H., Bissonnette, R., Bourcier, M., Gratton, D., Kunynetz, R. A., Poulin, Y., Rosoph, L. A., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12710 · Cited by 204
Hashmi, S., & Zeng, Q. T. (2006) · Coronary Artery Disease · doi:10.1097/01.mca.0000236288.94553.b4 · Cited by 191
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.037 · Cited by 189
Self-citationThe IL-23/IL-17 axis in psoriatic arthritis
Suzuki, E., Mellins, E. D., Gershwin, M. E., Nestle, F. O., & Adamopoulos, I. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.050 · Cited by 186
Simon, T., Taleb, S., Danchin, N., Laurans, L., Rousseau, B., Cattan, S., Montely, J.-M., Dubourg, O., Tedgui, A., Kotti, S., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs263 · Cited by 184
de Boer, O. J., van der Meer, J. J., Teeling, P., van der Loos, C. M., Idu, M. M., van Maldegem, F., Aten, J., & van der Wal, A. C. (2010) · The Journal of Pathology · doi:10.1002/path.2667 · Cited by 183
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model
Chiricozzi, A., Nograles, K. E., Johnson-Huang, L. M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K. M., Gulati, N., Mitsui, H., Guttman-Yassky, E., Suárez-Fariñas, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090284 · Cited by 180
Self-citationHuman mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Mashiko, S., Bouguermouh, S., Rubio, M., Baba, N., Bissonnette, R., & Sarfati, M. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.033 · Cited by 180
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
Self-citationMabuchi, T., Takekoshi, T., & Hwang, S. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101817 · Cited by 170
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Hohenberger, M., Cardwell, L. A., Oussedik, E., & Feldman, S. R. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329511 · Cited by 165
van Baarsen, L. G. M., Lebre, M. C., van der Coelen, D., Aarrass, S., Tang, M. W., Ramwadhdoebé, T. H., Gerlag, D. M., & Tak, P. P. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0426-z · Cited by 164
Innate Lymphoid Cells: Balancing Immunity, Inflammation, and Tissue Repair in the Intestine
Wojno, E. D. T., & Artis, D. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.10.003 · Cited by 163
Genetic and epigenetic basis of psoriasis pathogenesis
Chandra, A., Ray, A., Senapati, S., & Chatterjee, R. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.12.014 · Cited by 161
IL-17 targeted therapies for psoriasis
Chiricozzi, A., & Krueger, J. G. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.806483 · Cited by 160
Self-citationRussell, C. B., Rand, H., Bigler, J., Kerkof, K., Timour, M., Bautista, E., Krueger, J. G., Salinger, D. H., Welcher, A. A., & Martin, D. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301737 · Cited by 160
Cytokine production by human neutrophils: Revisiting the “dark side of the moon”
Tamassia, N., Bianchetto‐Aguilera, F., Arruda‐Silva, F., Gardiman, E., Gasperini, S., Calzetti, F., & Cassatella, M. A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12952 · Cited by 160
Mabuchi, T., Singh, T. P., Takekoshi, T., Jia, G.-F., Wu, X., Kao, M. C., Weiss, I. D., Farber, J. M., & Hwang, S. T. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.260 · Cited by 158
Erbel, C., Akhavanpoor, M., Okuyucu, D., Wangler, S., Dietz, A., Zhao, L., Stellos, K., Little, K. M., Lasitschka, F., Doesch, A. O., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400181 · Cited by 158
Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function
Dudeck, A., Suender, C. A., Kostka, S. L., von Stebut, E., & Maurer, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201040994 · Cited by 156
The role of IL 23 in the treatment of psoriasis
Puig, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1292137 · Cited by 156
TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic?
Marwaha, A., Leung, N. J., McMurchy, A. N., & Levings, M. K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00129 · Cited by 146
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data
Sakkas, L. I., & Bogdanos, D. P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.09.015 · Cited by 141
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Farahnik, B., Beroukhim, K., Abrouk, M. E., Nakamura, M., Zhu, T. H., Singh, R., Lee, K. M., Bhutani, T., & Koo, J. Y. M. (2016) · Dermatology and Therapy · doi:10.1007/s13555-016-0121-x · Cited by 138
Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis
Belasco, J., Louie, J. S., Gulati, N., Wei, N., Nograles, K. E., Fuentes‐Duculan, J., Mitsui, H., Suárez‐Fariñas, M., & Krueger, J. G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38995 · Cited by 137
Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin
Dyring‐Andersen, B., Geisler, C., Agerbeck, C., Lauritsen, J. P. H., Gúdjonsdottir, S. D., Skov, L., & Bonefeld, C. M. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12658 · Cited by 135
Safety of secukinumab in the treatment of psoriasis
Blauvelt, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221923 · Cited by 135
Self-citationKeijsers, R. R. M. C., Hendriks, A. G. M., van Erp, P. E. J., van Cranenbroek, B., van de Kerkhof, P. C. M., Koenen, H. J. P. M., & Joosten, I. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.526 · Cited by 133
Cellular sources of IL ‐17 in psoriasis: a paradigm shift?
Keijsers, R. R. M. C., Joosten, I., van Erp, P. E. J., Koenen, H. J. P. M., & van de Kerkhof, P. C. M. (2014) · Experimental Dermatology · doi:10.1111/exd.12487 · Cited by 128
Dermal IL‐17‐producing γδ T cells establish long‐lived memory in the skin
Hartwig, T., Pantelyushin, S., Croxford, A. L., Kulig, P., & Becher, B. (2015) · European Journal of Immunology · doi:10.1002/eji.201545883 · Cited by 120
The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications
Marinoni, B., Ceribelli, A., Massarotti, M. S., & Selmi, C. F. (2014) · Autoimmunity Highlights · doi:10.1007/s13317-013-0057-4 · Cited by 117
Leijten, E. F. A., van Kempen, T. S., Boes, M. L., Amelsfort, J. M. R. M.-V., Hijnen, D., Hartgring, S. A. Y., van Roon, J. A. G., Wenink, M. H., & Radstake, T. R. D. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39261 · Cited by 117
Chiricozzi, A., Suárez‐Fariñas, M., Fuentes‐Duculan, J., Cueto, I., Li, K., Tian, S., Brodmerkel, C. M., & Krueger, J. G. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14034 · Cited by 108
Self-citationReich, K., Leonardi, C. L., Langley, R. G. B., Warren, R. B., Bachelez, H., Romiti, R., Ohtsuki, M., Xu, W., Acharya, N. V., Solotkin, K. C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.027 · Cited by 99
Sexy again: the renaissance of neutrophils in psoriasis
Schön, M. P., Broekaert, S. M. C., & Erpenbeck, L. (2016) · Experimental Dermatology · doi:10.1111/exd.13067 · Cited by 98
Dermal γδ T cells – What have we learned?
O’Brien, R. L., & Born, W. K. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.011 · Cited by 88
Kim, T., Jee, H., Fuentes‐Duculan, J., Wu, W. H., Byamba, D., Kim, D., Kim, D. Y., Lew, D., Yang, W.-I., Krueger, J. G., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.534 · Cited by 88
Current Concepts in Psoriatic Arthritis: Pathogenesis and Management
de Vlam, K., Gottlieb, A. B., & Mease, P. J. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1833 · Cited by 87
Human mast cells capture, store, and release bioactive, exogenous IL-17A
Noordenbos, T., Blijdorp, I. C. J., Chen, S., Stap, J., Mul, E. P. J., Cañete, J. D. D., Lubberts, E., Yeremenko, N. G., & Baeten, D. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi1215-542r · Cited by 87
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
Blauvelt, A., Lebwohl, M., & Bissonnette, R. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.144 · Cited by 76
Self-citationThe role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer
Li, L., & Boussiotis, V. A. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.003 · Cited by 75
Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
Raychaudhuri, S. P., & Raychaudhuri, S. K. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1249-5 · Cited by 74
Muromoto, R., Hirao, T., Tawa, K., Hirashima, K., Kon, S., Kitai, Y., & Matsuda, T. (2016) · International Immunology · doi:10.1093/intimm/dxw011 · Cited by 72
CCR6 as a possible therapeutic target in psoriasis
Hedrick, M. N., Lonsdorf, A. S., Hwang, S. T., & Farber, J. M. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.504716 · Cited by 68
Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis
O’Rielly, D. D., & Rahman, P. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.07.002 · Cited by 64
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases
Nirula, A., Nilsen, J., Klekotka, P. A., Kricorian, G., Erondu, N., Towne, J. E., Russell, C. B., Martin, D. A., & Budelsky, A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew346 · Cited by 63
A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
Armstrong, A. W., Bukhalo, M., & Blauvelt, A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0206-4 · Cited by 62
Self-citationTamassia, N., Arruda-Silva, F., Calzetti, F., Lonardi, S., Gasperini, S., Gardiman, E., Bianchetto-Aguilera, F. M., Gatta, L. B., Girolomoni, G., Mantovani, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00795 · Cited by 61
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
Nakamura, M., Lee, K. J., Jeon, C., Sekhon, S., Afifi, L., Yan, D., Lee, K. M., & Bhutani, T. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0187-0 · Cited by 61
Wang, C. Q. F., Suárez‐Fariñas, M., Nograles, K. E., Mimoso, C. A., Shrom, D., Dow, E. R., Heffernan, M. P., Hoffman, R. W., & Krueger, J. G. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.268 · Cited by 59
Gaspari, A. A., & Tyring, S. K. (2015) · Dermatologic Therapy · doi:10.1111/dth.12251 · Cited by 56
A New Player on the Psoriasis Block: IL-17A- and IL-22-Producing Innate Lymphoid Cells
Ward, N. L., & Umetsu, D. T. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.216 · Cited by 56
Johnston, A. W. B., Guzman, A. M., Swindell, W. R., Wang, F., Kang, S., & Gudjonsson, J. E. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12937 · Cited by 56
Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin
Dyring‐Andersen, B., Honoré, T. V., Madelung, A. B., Bzorek, M., Simonsen, S., Clemmensen, S. N., Clark, R. A., Borregaard, N., & Skov, L. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15533 · Cited by 56
Gone but Not Forgotten: Lesional Memory in Psoriatic Skin
Clark, R. A. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.374 · Cited by 54
Chiricozzi, A., Romanelli, M., Saraceno, R., & Torres, T. R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1228872 · Cited by 50
Self-citationHarnessing the Therapeutic Potential of Th17 Cells
Byström, J., Taher, T. E. I., Muhyaddin, M. S., Clanchy, F. I. L., Mangat, P., Jawad, A. S., Williams, R. O., & Mageed, R. A. (2015) · Mediators of Inflammation · doi:10.1155/2015/205156 · Cited by 48
Targeting IL-17 in psoriatic arthritis
Wang, E. A., Suzuki, É., Maverakis, E., & Adamopoulos, I. E. (2017) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2017.17037 · Cited by 46
Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A
Li, Y., Golden, J. B., Camhi, M. I., Zhang, X., Fritz, Y., Diaconu, D., Ivanco, T. L., Simon, D. I., Kikly, K. K., McCormick, T. S., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.021 · Cited by 40
Johnson-Huang, L. M., Pensabene, C. A., Shah, K. R., Pierson, K. C., Kikuchi, T., Lentini, T., Gilleaudeau, P., Sullivan-Whalen, M. M., Cueto, I., Khatcherian, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030308 · Cited by 35
Ueyama, A., Imura, C., Fusamae, Y., Tsujii, K., Furue, Y., Aoki, M., Suzuki, M., Okuda, T., Oshima, I., Yasui, K., et al. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.10.007 · Cited by 32
Is Psoriatic Arthritis a Result of Abnormalities in Acquired or Innate Immunity?
Lories, R. J. U., & de Vlam, K. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0257-3 · Cited by 30
STAT-3–independent production of IL-17 by mouse innate-like αβ T cells controls ocular infection
Leger, A. J. S., Hansen, A. M., Karaüzüm, H., Horai, R., Yu, C., Laurence, A. D. J., Mayer-Barber, K. D., Silver, P. B., Villasmil, R., Egwuagu, C. E., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170369 · Cited by 27
Tamarozzi, F., Wright, H. L., Thomas, H. B., Edwards, S. W., & Taylor, M. J. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.025 · Cited by 23
IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease
Mitra, A., Raychaudhuri, S., & Raychaudhuri, S. P. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(14)70015-8 · Cited by 22
Rieder, E. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.052 · Cited by 6
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424
Self-citationReich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M.-C., Branigan, P., & Blauvelt, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31773-8 · Cited by 381
Self-citationRole of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360
Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 315
Self-citation
Metadata
- Authors
- Blauvelt, A., & Chiricozzi, A.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2018-08-14
- Volume
- 55
- Issue
- 3
- Pages
- 379-390
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W2887422108
- Cited by
- 789
- References
- 135
- FWCI
- 18.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.